Latest Posts › Biotechnology

Share:

BIO IPCC Panel Discusses Impact of Myriad-Mayo Guidance

Yesterday, we reported on a session of the Biotechnology Industry Organization (BIO) Intellectual Property Counsel's Committee fall conference, which took place earlier this week in Nashville, TN, in which the U.S. Patent and...more

11/14/2014 - Biotechnology Genetic Materials Guidance Update Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical USPTO

USPTO Provides Update on Status of Revised Myriad-Mayo Guidance

During a session of the Biotechnology Industry Organization (BIO) Intellectual Property Counsels Committee (IPCC) fall conference, which took place this week in Nashville, TN, the U.S. Patent and Trademark Office provided a...more

11/13/2014 - Biotechnology Genetic Materials Guidance Update Myriad-Mayo Patent-Eligible Subject Matter Patents USPTO

Examination of Myriad-Mayo Guidance Comments -- University Community Joint Comment

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

10/29/2014 - Biotechnology Mayo v. Prometheus Myriad Myriad-Mayo Patents Pharmaceutical Patents Universities USPTO

Examination of Myriad-Mayo Guidance Comments -- BIO Joint Comment

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

10/24/2014 - AMP v Myriad Biotechnology Draft Guidance Genetic Materials Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Manufacturers Public Comment Trade Associations USPTO

Sherry Knowles Addresses Real World Impact of Myriad-Mayo Guidance at BIO Symposium

Last month, at the Biotechnology Industry Organization (BIO) IP & Diagnostics Symposium in Alexandria, VA, Sherry Knowles of Knowles IP Strategies addressed the impact of the U.S. Patent and Trademark Office's Myriad-Mayo...more

10/16/2014 - Biotechnology Guidance Update Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Patents USPTO

Examination of Myriad-Mayo Guidance Comments -- International Bioindustry Associations

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/12/2014 - Biotechnology Mayo v. Prometheus Myriad Myriad-Mayo Patent Litigation Patent-Eligible Subject Matter Patents Pharmaceutical Pharmaceutical Patents Public Comment Rulemaking Process USPTO

Examination of Myriad-Mayo Guidance Comments -- ACLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/6/2014 - ACLU Biotechnology Chemicals CLS Bank v Alice Corp Mayo v. Prometheus Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Public Comment Section 101 USPTO

Software Sector Leads Pack in 2Q Venture Funding and Biotech Sector Finishes Second

Last week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the second quarter of 2014. ...more

7/21/2014 - Biotechnology Funding Medical Devices Patents Pharmaceutical Pricewaterhousecoopers Software Venture Capital

AbbVie Deutschland GmbH v. Janssen Biotech, Inc. (Fed. Cir. 2014) - Absent Description of Representative Species to Support Entire...

Last week, in AbbVie Deutschland GmbH v. Janssen Biotech, Inc., the Federal Circuit affirmed judgments by the District Court for the District of Massachusetts in infringement and interference actions involving AbbVie...more

7/11/2014 - Biotechnology Patent Infringement Patent Litigation Patents

Software Sector Leads First Quarter Venture Funding to Thirteen Year High; Biotech Sector Finishes Second (Again)

Earlier this month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the first quarter of...more

5/1/2014 - Biotechnology Medical Devices Software Venture Funding

USPTO Tries to Address Public Misunderstandings Regarding Myriad-Mayo Guidance

The U.S. Patent and Trademark Office spent the entire afternoon session of today's biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting focusing on the guidance memorandum for determining the subject...more

4/17/2014 - Biotechnology Myriad Patent-Eligible Subject Matter Pharmaceutical USPTO

GEN and FiercePharma Compile Lists of Top Selling Drugs for 2013

Earlier this month, Genetic Engineering & Biotechnology News released its list of the top 25 best-selling drugs worldwide for 2013. GEN's list, which the journal released on March 3 (see "The Top 25 Best-Selling Drugs of...more

3/27/2014 - Biotechnology Pharmaceutical Prescription Drugs

Biotech Venture Funding Rebounded in 2013 After Strong Fourth Quarter

Earlier this month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for 2013. The report,...more

1/27/2014 - Biotechnology Patents Pharmaceutical Venture Capital

More Q&A from Webinar on Top Patent Law Stories of 2013

On Tuesday, we presented a live webinar on the "Top Patent Law Stories of 2013." The webinar covered ten of the fourteen stories that made it onto Patent Docs seventh annual list of top biotech/pharma patent stories. Posts...more

1/24/2014 - 23andMe America Invents Act AMP v Myriad Biotechnology Bowman v Monsanto FTC v Actavis Innovation Act Life Sciences Monsanto Myriad Patent Infringement Patent Litigation Patent Reform Patent Trolls Patents Pharmaceutical SCOTUS

Top Three Stories of 2013

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/6/2014 - America Invents Act AMP v Myriad Biotechnology Bowman v Monsanto DNA First-to-File First-to-Invent Genetic Materials Genetically Engineered Seed Human Genes Inventors Monsanto Patent Infringement Patent Litigation Patent Reform Patents Pharmaceutical SCOTUS

Top Stories of 2013: #7 to #10

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/2/2014 - Ambry Biotechnology BRCA DNA Human Genes Life Sciences Myriad Patent Litigation Patents Pharmaceutical

Top Stories of 2013: #11 to #14

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/2/2014 - 23andMe Biosimilars Biotechnology BPCIA Medtronic v Boston Scientific Patents Pharmaceutical Unified Patent Court

Tufts Report Shows Dramatic Shift from Small Molecule to Biologic Drugs

Last week, the Tufts Center for the Study of Drug Development (CSDD) at Tufts University released a report showing that the pharmaceutical industry has dramatically shifted its focus from a historical concentration on small...more

11/20/2013 - Biotechnology Pharmaceutical Prescription Drugs

Bioethicists "Urge Maximal Transparency" in Response to 23andMe Patent

Last week, we discussed a patent, recently issued to 23andMe, Inc., that has created some controversy. The patent, U.S. Patent No. 8,543,339, is directed to a system for identifying a preferred gamete donor from among the...more

10/15/2013 - 23andMe Biotechnology Ethics Genetic Testing Human Genes Patents

23andMe Patent Creates Controversy

A patent issued to 23andMe, Inc. last month has created some controversy, and in response, the biotech company, based in Mountain View, California, has posted its side of the story on the 23andMe blog. The patent, U.S....more

10/9/2013 - 23andMe Biotechnology DNA Genetic Materials Human Genes Patent-Eligible Subject Matter Patents

Coalition Opposes Expansion of AIA ยง 18

Last week, a coalition of more than 100 companies and organizations including the Biotechnology Industry Organization (BIO), the California Healthcare Institute (CHI), and Eli Lilly & Company, sent a letter to Congressional...more

9/24/2013 - America Invents Act Biotechnology First-to-File First-to-Invent Patent Reform Patents

NEJM Perspective Calls for Recalibration of Bayh-Dole Act

In a perspective published in the August 29 issue of the New England Journal of Medicine, Dr. Howard Markel outlines the events leading up to the enactment of the Bayh-Dole Act and states that "a review of [the Act's] origins...more

9/11/2013 - Bayh-Dole Act Biotechnology Healthcare Professionals Proposed Amendments

Op-Eds in The Scientist Debate Impact of the AIA

Two Op-Eds appearing in The Scientist over the summer present competing views on the impact of the Leahy-Smith America Invents Act. In an article published in July, Dr. George Lewis, the Chief Scientific Officer and...more

9/6/2013 - America Invents Act Biotechnology First-to-File First-to-Invent Patent Reform Small Business

SkinMedica, Inc. v. Histogen Inc. (Fed. Cir. 2013)

On August 23, in SkinMedica, Inc. v. Histogen Inc., the Federal Circuit determined that the District Court for the Southern District of California did not err in construing the phrase "culturing . . . cells in...more

9/4/2013 - Biotechnology Infringement Patent Litigation Patents Pharmaceutical

BIO Reiterates Support for 12-Year Data Exclusivity Period for Biologics

Last month, in a letter to the U.S. Trade Representative, Ambassador Michael Froman, Biotechnology Industry Organization (BIO) President and CEO James Greenwood expressed support for the efforts of the Obama Administration to...more

8/21/2013 - Affordable Care Act Biologics Biotechnology Free Trade Agreement Pharmaceutical Prescription Drugs Trans-Pacific Partnership

36 Results
|
View per page
Page: of 2